19 October-1 December 2020
The 51st Union World Conference On Lung Health
REGISTER NOW

Sessions

All Sessions
keyboard_arrow_down
keyboard_arrow_down Show filters keyboard_arrow_up Hide filters
  • All Tracks
  • Community Connect
  • Channel 1
  • Channel 2
  • Channel 3
  • Channel 4
  • Channel 5
  • Channel 6
  • Channel 7
  • E-posters
  • Workshops
Channel 3
SS-05-Leave no one behind: we can defeat COVID-19 and latent TB infection together
event_note
Loading...
query_builder 09:45 - 10:45 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Satellite session
mic English
SS-05-Leave no one behind: we can defeat COVID-19 and latent TB infection together
*Please scroll down for more information*
Organised by: QIAGEN
Global health experts are working to slow the COVID-19 pandemic – but responding to COVID-19 has also forced disruption of existing TB control programs around the globe. QIAGEN is committed to fighting COVID-19 and TB, developing innovative new testing solutions so that no one is left behind in the battle against pandemic lung diseases. Join our interactive symposium as we discuss QIAGEN's evolving solutions in two parts:
Part 1. QIAreach QuantiFERON-TB: A simple and accurate solution for decentralized TB infection screening
Currently in development, the QIAreach QuantiFERON-TB is a field-friendly, portable latent TB testing solution that will expand access to TB testing where it's needed the most. QIAGEN's assay development team will introduce the test and provide a scientific review of early performance data. This will be followed by first-hand experiences from ongoing trials of the test conducted in Zambia.

Part 2. Tackling TB and COVID-19 together: From centralized to decentralized testing
Stop TB and the WHO have highlighted the overlapping symptoms and risk groups shared by COVID-19 and TB. QIAGEN's Dr. Masae Kawamura will discuss shared disease etymologies and introduce QIAGEN's portfolio of cutting-edge solutions for both centralized and decentralized testing. Centralized solutions include: QuantiFERON-TB Gold Plus (TB) and QIAstat-Dx Respiratory SARS-CoV-2 Panel (SARS-CoV-2). Decentralized solutions include: QIAreach QuantiFERON-TB (TB), QIAreach Anti-SARS-CoV-2 Total (not available in all markets) and QIAreach SARS-CoV-2 Antigen Test (SARS-CoV-2).
Products and product claims may differ from country to country based on regulations and approvals. Contact your country representative for further details.
QIAreach QuantiFERON-TB and QIAreach SARS-CoV-2 Antigen are currently under development and coming soon. QIAreach QuantiFERON-TB is intended for high-TB-burden countries.

09:45 - 09:50: Introduction


09:50 - 09:57: QIAreach QuantiFERON-TB: a simple and accurate solution for decentralised TB infection screening Currently in development, the QIAreach QuantiFERON-TB is a field-friendly, portable latent tuberculosis (TB) testing solution that will expand access to TB testing where it's needed the most. QIAGEN's assay development team will introduce the test and provide a scientific review of early performance data. This will be followed by first-hand experiences from ongoing trials of the test conducted in Zambia.

Kwame Shanaube

09:57 - 10:11: Tackling TB and COVID-19 together: from centralised to decentralised testing Stop TB and the World Health Organization have highlighted the overlapping symptoms and risk groups shared by COVID-19 and tuberculosis (TB). QIAGEN's Dr. Masae Kawamura will discuss shared disease etymologies and introduce QIAGEN's portfolio of cutting-edge solutions for both centralised and decentralised testing. Centralised solutions include: QuantiFERON-TB Gold Plus (TB) and QIAstat-Dx Respiratory SARS-CoV-2 Panel (SARS-CoV-2). Decentralised solutions include: QIAreach QuantiFERON-TB (TB), QIAreach Anti-SARS-CoV-2 Total (not available in all markets) and QIAreach SARS-CoV-2 Antigen Test (SARS-CoV-2).

Masae Kawamura

Loading...
Channel 2
SS-09-Testing to turn the COVID-19 pandemic: the opportunity for TB
event_note
Loading...
query_builder 18:15 - 19:45 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Satellite session
mic English
SS-09-Testing to turn the COVID-19 pandemic: the opportunity for TB
*Please scroll down for more information*
Organised by: FIND and The Global Fund to Fight AIDS, Tuberculosis and Malaria.
FIND and The Global Fund are co-convenors of the Access to COVID-19 Tools (ACT) Accelerator Diagnostics Pillar – part of a  global collaboration to accelerate the development, production and equitable access to new COVID-19 tools including diagnostics. In addition  to developing new tests, the ACT Accelerator Diagnostics Pillar aims to strengthen low- and middle-income countries’ ability to procure, import, distribute tests  and manage data to assist governments in decision making. Tests developed to enable rapid diagnosis of tuberculosis (TB) are now being  used to diagnose COVID-19. Could global diagnostic networks and new COVID-19 tools be utilised to combat TB in the future?

18:15 - 18:19: Introduction


18:19 - 18:53: Panel discussion: TB, COVID-19 and ACT-A Dx – mitigating the impact and protecting TB gains Diagnostics are critical to any health response and essential to limit the spread of disease. However, greater innovation and  funding are needed to ensure tests can be deployed quickly and easily to everyone who needs one. In deploying new tools, programmes must  aim for integrated service delivery to balance supply and deployment constraints. FIND and The Global Fund are co-convenors of the Access  to COVID-19 Tools (ACT) Accelerator Diagnostics Pillar under which 50 new diagnostic tests have been evaluated. A new rapid antigen test  will soon be ready for roll out and 17 million tests have been delivered to low-and middle-income countries. The ACT-Accelerator experience provides vital lessons on  what a blueprint for successful pandemic preparedness and response could look like for diagnostics. What lessons can we learn for tuberculosis (TB), which is already experiencing the knock-on impact of COVID-19, and how do we protect our gains in TB while successfully beating the pandemic?

Catharina Boehme
John Nkengasong
Kuldeep Singh Sachdeva
Peter Sands

18:53 - 19:03: TB tests being 'repurposed' for COVID-19: experience with Truenat, GeneXpert, digital X-rays and next-generation  sequencing The COVID-19 pandemic has seen existing diagnostics for tuberculosis (TB) being repurposed or used to diagnose COVID-19. Cepheid  Inc’s GeneXpert® MTB/RIF - for the rapid diagnosis of TB and detection of rifampicin-resistance - is being used to run a newly developed  COVID-19 test. Similarly, Indian diagnostic manufacturer, Molbio, whose Truenat™ test was recently endorsed by the World Health Organization received approval  from India’s regulatory authority for a Truenat COVID-19 test, expanding the number of existing diagnostics platforms repurposed for COVID-19. Additionally, digital chest Xray can be deployed along with artificial intelligence-based tools for both TB and COVID-19.  Leveraging ongoing efforts in enabling next-generation sequencing solutions for drug-resistant TB detection under the Unitaid-funded  Seq&Treat project, FIND has compiled a landscape and a preliminary assessment of sequencing utility and capacity in low-and middle-income countries for COVID-19 surveillance and management. We’ll share in-country implementers' experience repurposing TB tests for COVID-19.

Morten Ruhwald

19:03 - 19:13: Ending TB amid the COVID-19 pandemic: a community-led response The COVID-19 pandemic has had tremendous impact on tuberculosis (TB) programmes and activated disruptions along the care spectrum, from screening to diagnosis to the treatment of people with TB. While efforts have been made through the contribution of the Global Fund and stakeholders worldwide, impactful gains were undone. While barriers were being addressed there was an increase in the barriers faced, including  access to services, along with heightened stigma and the dual stigma of COVID-19 and TB. There is a need for meaningful engagement and for strengthening community engagement and linkages in order to address barriers collectively and to find solutions. Community systems and community-led  monitoring can support the implementation of catch-up plans so that efforts in finding the missing people with TB can be reinforced and barriers can be mitigated.
This session highlights experiences of civil society and partners and their role in the mitigation of the impact of COVID-19 on TB and on the road ahead.

Carol Nawina (Nyirenda) Kachenga

19:13 - 19:23: Access to TB diagnostic services during COVID-19: experience from South Africa In many of the countries most heavily affected by HIV, tuberculosis (TB) and malaria, the knock-on impact of COVID-19 on these three  diseases, in terms of incremental deaths, may outweigh the direct impact of the virus. The Global Fund is already witnessing the impact of  COVID-19 on the fight against HIV, TB and malaria across the countries where itinvests. For example, TB laboratory services are under acute  pressure, with 20% experiencing high or very high levels of disruption, with many of the advanced diagnostics instruments put in place to  diagnose TB now being used for testing for COVID-19. We’ll hear from South Africa – a country with a high TB and HIV burden which is now addressing  the deadly pandemic - on scale-up of COVID-19 testing and integration of testing services for COVID-19 and TB.

Wendy Stevens

19:23 - 19:45: Q&A session


Loading...
Processing. Please wait.
Loading...